JNJ
Johnson & Johnson · Healthcare
240.97
0.85%(-2.07)
Prev. Close243.03
0.85%(+2.06)
Pre-marketLast Updated: — ET
52W L: $141.5052W H: $251.71
$241.97
CHG+5.85 (+2.48%)
H$247.21
L$232.01
VOL96M
JNJ (1h)
Johnson & Johnson · Healthcare
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Coca-Cola (NYSE:KO) both closed out 2025 with Q4 earnings and have raised dividends for 63 consecutive years.
A safe stock is a business that can take a punch, keep generating cash flow, keep paying shareholders, and still look stronger a few years later. When debt is low, management has room to maneuver. It can keep investing, protect the dividend, pursue acquisitions, or simply ride out a rough period without making desperate decisions. Safety is not only about defensiveness. Sometimes, the safest company is simply the one executing so well that it keeps compounding no matter what the market feels this quarter.
Aberdeen Group plc lifted its stake in Johnson and Johnson (NYSE: JNJ) by 1.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,538,487 shares of the company's stock after acquiring an additional 47,996 shares during the period. Johnson and Johnson accounts for about
HF Advisory Group LLC boosted its holdings in Johnson and Johnson (NYSE: JNJ) by 305.9% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,887 shares of the company's stock after purchasing an additional 14,987 shares during the
Johnson & Johnson earns a Buy rating, driven by the FDA approval of its Tecvayli and Darzalex Faspro combination for R/R multiple myeloma, delivering best-in-class efficacy. This combination therapy achieved an 83.4% 36-month progression-free survival rate, significantly outperforming the control arm and expanding JNJ's addressable market. JNJ's oncology pipeline, especially in hematology, is positioned to offset Stelara's LOE, targeting $50B in oncology sales and $125B total revenue by 2030.
Defensive healthcare stocks such as Johnson & Johnson and CVS tend to outperform in recessions. Growth healthcare stocks offer higher risk and potential reward, less tied to economic cycles.
HEWSON MARILLYN A
director
206.492 SH @ $0.00
2026-03-10
HEWSON MARILLYN A
director
75.256 SH @ $0.00
2025-03-04
Pinto Daniel E
director
129.058 SH @ $0.00
2026-03-10
Woods Eugene A.
director
154.869 SH @ $0.00
2026-03-10
Decker Robert J
officer: VP Corporate Controller
4,075 SH @ $115.67
2026-02-27
Decker Robert J
officer: VP Corporate Controller
4,075 SH @ $247.87
2026-02-27
Decker Robert J
officer: VP Corporate Controller
4,075 SH @ $115.67
2026-02-27
Schmid Timothy
officer: EVP, WW Chair, MedTech
1,322 SH @ $245.66
2026-02-20